吲哚美辛杂质13 | 807614-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 吲哚美辛杂质13
• 英文名称: [1-(3-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
• 英文别名: 2-[1-(3-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
• CAS: 807614-94-4
• 化学式: C₁₉H₁₆ClNO₄
• 分子量: 357.793
• InChiKey: PXXTUBBLCCJTKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  吲哚美辛杂质13 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 [1-(3-chlorobenzoyl)-5-hydroxy-2-methyl-1H-indol-3-yl]acetic acid
  参考文献：
  名称：

  Synthesis of COX-2 and FAAH inhibitors

  摘要：

  描述了制备对COX-2抑制剂有用的吲哚和在这些方法中有用的中间体的方法。

  公开号：

  US20050234244A1
• 作为产物：
  描述：

  乙酰丙酸 、 3-chloro-N-(4-methoxyphenyl)benzohydrazide hydrochloride 在 氮气 、 ice water 作用下， 以 溶剂黄146 为溶剂， 反应 4.0h， 以to give [1-(3-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid (41) (2.0 g, 73%) as an off white solid, mp 90-92° C.的产率得到吲哚美辛杂质13
  参考文献：
  名称：

  Synthesis of COX-2 and FAAH inhibitors

  摘要：

  本发明提供了一种制备对COX-2具有抑制作用的吲哚化合物的方法，以及用于该方法的中间体。

  公开号：

  US20050234244A1

文献信息

• METHODS FOR THE PROTECTION OF MEMORY AND COGNITION
  申请人：Microbia, INC.

  公开号：EP1628532A2

  公开（公告）日：2006-03-01
• Methods for the protection of memory and cognition
  申请人：Cali M. Brian

  公开号：US20050004104A1

  公开（公告）日：2005-01-06

  The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or COX-2 at therapeutically relevant doses, these compounds are far less likely to cause gastrointestinal ulceration than is indomethacin, which is known to inhibit both COX-1 and COX-2. Certain of the compounds inhibit the activity of DAO at therapeutically relevant doses. Among the memory disorders that can be treated are AD, mild cognitive impairment (MCI; a common precursor to AD), and memory loss or cognitive impairment associated with vascular dementias, amnesia, dementia, AIDS dementia, Huntington's Disease, hydrocephalus, depression, Pick's Disease, Creutzfeldt-Jakob Syndrome, electroconvulsive therapy, or Parkinson's Disease.
• Modulators of CRTH2 Activity
  申请人：Chien Yueh-Tyng

  公开号：US20070161698A1

  公开（公告）日：2007-07-12

  Modulators of the CRTH2 receptor and their use in the treatment of various disorders, including asthma are described.
• US7205329B2
  申请人：——

  公开号：US7205329B2

  公开（公告）日：2007-04-17
• [EN] METHODS FOR THE PROTECTION OF MEMORY AND COGNITION<br/>[FR] PROCEDES DESTINES A LA PROTECTION DE LA MEMOIRE ET DE LA COGNITION
  申请人：MICROBIA INC

  公开号：WO2004108085A2

  公开（公告）日：2004-12-16

  The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or COX-2 at therapeutically relevant doses, these compounds are far less likely to cause gastrointestinal ulceration than is indomethacin, which is known to inhibit both COX-1 and COX-2. Certain of the compounds inhibit the activity of DAO at therapeutically relevant doses. Among the memory disorders that can be treated are AD, mild cognitive impairment (MCI; a common precursor to AD), and memory loss or cognitive impairment associated with vascular dementias, amnesia, dementia, AIDS dementia, Huntington's Disease, hydrocephalus, depression, Pick's Disease, Creutzfeldt-Jakob Syndrome, electroconvulsive therapy, or Parkinson's Disease.